166 related articles for article (PubMed ID: 70492)
21. Evaluation of the immune responses following co-administration of PilQ and type b-flagellin from Pseudomonas aeruginosa in the burn mouse model.
Bakht Azad S; Nikokar I; Faezi S; Rasooly S; Mahdavi M
Microb Pathog; 2018 Oct; 123():426-432. PubMed ID: 30075242
[TBL] [Abstract][Full Text] [Related]
22. Pharmacodynamic and protective properties of a murine lipopolysaccharide-specific monoclonal antibody in experimental Pseudomonas aeruginosa pneumonia in mice.
Oishi K; Sonoda F; Miwa H; Tanaka H; Watanabe K; Matsumoto K; Pollack M
Microbiol Immunol; 1991; 35(12):1131-41. PubMed ID: 1808464
[TBL] [Abstract][Full Text] [Related]
23. Human anti-Pseudomonas aeruginosa outer membrane proteins IgG cross-protective against infection with heterologous immunotype strains of P. aeruginosa.
Lee NG; Ahn BY; Jung SB; Kim YG; Lee Y; Kim HS; Park WJ
FEMS Immunol Med Microbiol; 1999 Sep; 25(4):339-47. PubMed ID: 10497864
[TBL] [Abstract][Full Text] [Related]
24. Bivalent flagellin immunotherapy protects mice against Pseudomonas aeruginosa infections in both acute pneumonia and burn wound models.
Ahmadi H; Behrouz B; Irajian G; Amirmozafari N; Naghavi S
Biologicals; 2017 Mar; 46():29-37. PubMed ID: 28065582
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of human gamma-globulin preparation in experimental pseudomonas aeruginosa infections in mice and its mode of action.
Kamimura T
Arzneimittelforschung; 1984; 34(11):1528-34. PubMed ID: 6084512
[TBL] [Abstract][Full Text] [Related]
26. Passive protection of mice against Pseudomonas aeruginosa by serum from recently vaccinated mice.
Jones RJ; Lilly HA; Lowbury EJ
Br J Exp Pathol; 1971 Jun; 52(3):264-70. PubMed ID: 4996963
[TBL] [Abstract][Full Text] [Related]
27. Characterisation of mouse monoclonal antibodies produced by immunisation with a single serotype component of a polyvalent Pseudomonas aeruginosa vaccine.
Barclay GR; Yap PL; McClelland DB; Jones RJ; Roe EA; McCann MC; Micklem LR; James K
J Med Microbiol; 1986 Feb; 21(1):87-90. PubMed ID: 3081727
[TBL] [Abstract][Full Text] [Related]
28. [The necessity of i.v. human immunoglobulin therapy for Pseudomonas aeruginosa infection].
Nishimura T
Nihon Rinsho; 1991 Oct; 49(10):2431-40. PubMed ID: 1721099
[No Abstract] [Full Text] [Related]
29. [The protective activity of 2 normal immunoglobulin preparations for intravenous administration in experimental Pseudomonas aeruginosa infection].
Vasilev ChL; Veleva KV; Tekelieva RKh; Pencheva PI
Zh Mikrobiol Epidemiol Immunobiol; 1991 Feb; (2):54-6. PubMed ID: 1907793
[TBL] [Abstract][Full Text] [Related]
30. Post-exposure immunization by capsid-modified AdC7 vector expressing Pseudomonas aeruginosa OprF clears P. aeruginosa respiratory infection.
Gomi R; Sharma A; Wu W; Sung B; Worgall S
Vaccine; 2017 Dec; 35(51):7174-7180. PubMed ID: 29126807
[TBL] [Abstract][Full Text] [Related]
31. Immunization with Pseudomonas aeruginosa outer membrane vesicles stimulates protective immunity in mice.
Zhang X; Yang F; Zou J; Wu W; Jing H; Gou Q; Li H; Gu J; Zou Q; Zhang J
Vaccine; 2018 Feb; 36(8):1047-1054. PubMed ID: 29406241
[TBL] [Abstract][Full Text] [Related]
32. Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa.
Zweerink HJ; Gammon MC; Hutchison CF; Jackson JJ; Lombardo D; Miner KM; Puckett JM; Sewell TJ; Sigal NH
Infect Immun; 1988 Aug; 56(8):1873-9. PubMed ID: 3135264
[TBL] [Abstract][Full Text] [Related]
33. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR
Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231
[TBL] [Abstract][Full Text] [Related]
34. Protective effects of S-sulfonated human gamma globulin against experimental infections in mice.
Tomioka H; Iwamura Y; Suzuki Y; Ohtomo S; Hashimoto Y
Infect Immun; 1980 Nov; 30(2):329-36. PubMed ID: 6160106
[TBL] [Abstract][Full Text] [Related]
35. Comparative anti-Pseudomonas aeruginosa activity of chemically modified and native immunoglobulin G (human), and potentiation of antibiotic protection against Pseudomonas aeruginosa and group B Streptococcus in vivo.
Collins MS; Dorsey JH
Am J Med; 1984 Mar; 76(3A):155-60. PubMed ID: 6424444
[TBL] [Abstract][Full Text] [Related]
36. The role of cytophilic IgG3 antibody in T cell-mediated resistance to infection with the extracellular bacterium, Pseudomonas aeruginosa.
Markham RB; Pier GB; Schreiber JR
J Immunol; 1991 Jan; 146(1):316-20. PubMed ID: 1898604
[TBL] [Abstract][Full Text] [Related]
37. T lymphocyte-mediated protection against Pseudomonas aeruginosa infection in granulocytopenic mice.
Powderly WG; Pier GB; Markham RB
J Clin Invest; 1986 Aug; 78(2):375-80. PubMed ID: 2426306
[TBL] [Abstract][Full Text] [Related]
38. A diphasic immune response against bacteria in the American cockroach.
Faulhaber LM; Karp RD
Immunology; 1992 Feb; 75(2):378-81. PubMed ID: 1551700
[TBL] [Abstract][Full Text] [Related]
39. Establishment of stable cell lines producing anti-Pseudomonas aeruginosa monoclonal antibodies and their protective effects for the infection in mice.
O'Oka H; Chonan E; Mizutani K; Fukuda T; Kuroiwa Y; Ono Y; Shigeta S
Microbiol Immunol; 1992; 36(12):1305-16. PubMed ID: 1287405
[TBL] [Abstract][Full Text] [Related]
40. Common protective antigen between Pseudomanas aeruginosa and Vibrio cholerae.
Yamamoto A; Homma JY; Ghoda A; Ishihara T; Takeuchi S
Jpn J Exp Med; 1979 Dec; 49(6):383-90. PubMed ID: 120454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
